# A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

> **NCT04540497** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 135 (actual)

## Conditions studied

- IgG4 Related Disease

## Interventions

- **DRUG:** Inebilizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04540497
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-04
- **Primary completion:** 2024-04-09
- **Final completion:** 2028-10-31
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540497, "A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04540497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*